WGBS-upgaded:
WaferGen Bio-systems, Inc. (NASDAQ:WGBS) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Friday, Market Beat Ratings reports. The firm currently has a $1.00 price target on the stock. Zacks Investment Research‘s target price would suggest a potential upside of 21.21% from the company’s current price.
According to Zacks, “WaferGen Biosystems, Inc., a development stage company, engages in the development, manufacture, and sale of systems for gene expression, genotyping, and stem cell research for the life sciences, pharmaceutical industries, biomarker discovery and diagnostic products industries. The company is actively developing its SmartChip(TM) product for the gene expression and genotyping markets. This innovative system, combined with next-generation chemistry and optimized assays being developed by WaferGen, promises to deliver significant speed and cost advantages to researchers in the gene expression and genotyping markets. It offers SmartSlide Micro-Incubation system that provides a controlled environment and physiological conditions for imaging studies, allowing researchers to characterize, differentiate, and proliferate various cells. WaferGen’s revolutionary systems are the first of their kind, providing researchers with critical performance advantages that are not available with existing technologies. “
Shares of WaferGen Bio-systems (NASDAQ:WGBS) traded down 10.336% during mid-day trading on Friday, reaching $0.825. The company’s stock had a trading volume of 1,558,992 shares. WaferGen Bio-systems has a 12 month low of $0.74 and a 12 month high of $5.89. The stock’s market capitalization is $11.93 million. The company has a 50 day moving average price of $0.91 and a 200 day moving average price of $2.01.
WaferGen Bio-systems (NASDAQ:WGBS) last issued its quarterly earnings results on Tuesday, November 10th. The company reported ($0.61) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.61). The business earned $2 million during the quarter, compared to analyst estimates of $2 million. On average, equities research analysts anticipate that WaferGen Bio-systems will post ($2.42) earnings per share for the current fiscal year.
